Diagnostic and treatment strategies in mucopolysaccharidosis VI

• Autor(a) principal: Vairo, Filippo Pinto e
• Data de Publicação: 2015
• Outros Autores: Federhen, Andressa, Baldo, Guilherme, Burin, Maira Graeff, Riegel, Mariluce, Leistner-Segal, Sandra, Giugliani, Roberto
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Institucional da UFRGS
• Texto Completo: http://hdl.handle.net/10183/194311
• topic: Mucopolissacaridose VI; Doenças por armazenamento dos lisossomos; Terapia de reposição de enzimas; N-acetilgalactosamina-4-sulfatase; Mucopolysaccharidosis VI; Lysosomal storage diseases; Enzyme replacement therapy; Arylsulfatase b; Dermatan sulfate; Maroteaux lamy syndrome

Mucopolysaccharidosis VI (MPS VI) is a very rare autosomal recessive disorder caused by mutations in the ARSB gene, which lead to deficient activity of the lysosomal enzyme ASB. This enzyme is important for the breakdown of the glycosaminoglycans (GAGs) dermatan sulfate and chondroitin sulfate, which accumulate in body tissues and organs of MPS VI patients. The storage of GAGs (especially dermatan sulfate) causes bone dysplasia, joint restriction, organomegaly, heart disease, and corneal clouding, among several other problems, and reduced life span. Despite the fact that most cases are severe, there is a spectrum of severity and some cases are so attenuated that diagnosis is made late in life. Although the analysis of urinary GAGs and/or the measurement of enzyme activity in dried blood spots are useful screening methods, the diagnosis is based in the demonstration of the enzyme deficiency in leucocytes or fibroblasts, and/or in the identification of pathogenic mutations in the ARSB gene. Specific treatment with enzyme replacement has been available since 2005. It is safe and effective, bringing measurable benefits and increased survival to patients. As several evidences indicate that early initiation of therapy may lead to a better outcome, newborn screening is being considered for this condition, and it is already in place in selected areas where the incidence of MPS VI is increased. However, as enzyme replacement therapy is not curative, associated therapies should be considered, and research on innovative therapies continues. The management of affected patients by a multidisciplinary team with experience in MPS diseases is highly recommended.